Merck
-
Gilead, Merck present pivotal Phase 3 Islend data for first once-weekly oral HIV regimen
Researchers presented the findings at the 26th International AIDS Conference in Rio de Janeiro, Brazil.
-
Merck secures landmark FDA approval for cholesterol pill Lipfendra
The approval marks the first oral PCSK9 inhibitor, offering patients an alternative to injectable therapies traditionally used to reduce LDL cholesterol levels.
-
Merck KGaA to acquire Bio-Techne for US$11.3B in major life sciences expansion
The acquisition is expected to strengthen Merck’s position in the rapidly growing life sciences sector, particularly in areas such as cell and gene therapy, precision diagnostics, multi-omics research, and biopharmaceutical manufacturing.
-
Protillion Biosciences secures US$510M Merck deal for AI biologics discovery
The agreement brings together Protillion’s computational biology platform with Merck’s established drug development expertise to support the discovery of next-generation therapies.
-
Merck expands HIV portfolio with FDA approval of Idvynso single-tablet regimen
The tablet combines 100 mg of doravirine and 0.25 mg of islatravir in a once-daily formulation.
-
Merck completes US$6.7B acquisition of Terns Pharmaceuticals to strengthen the leukemia drug pipeline
Terns has now become a wholly owned subsidiary of Merck, and its common stock has ceased trading on the Nasdaq Global Select Market.
-
European Commission approves Merck’s Enflonsia for RSV prevention in infants
The approval grants the pharmaceutical giant the right to market Enflonsia across all 27 member states of the European Union, as well as Iceland, Liechtenstein, and Norway.
-
Merck restructures China vaccine deal as Gardasil demand collapses
This shift applies to all three Merck vaccines distributed by Zhifei: Gardasil, the rotavirus vaccine RotaTeq, and the pneumococcal vaccine Pneumovax 23.
-
MSD acquires Cidara Therapeutics for USD9.2B to strengthen influenza prevention pipeline
The pharmaceutical giant will pay USD221.50 per share in cash to purchase the US biotech company, which has developed an innovative platform called drug-Fc conjugates (DFCs).
-
Merck KGaA enters USD3B AI drug discovery partnership with Valo Health to target Parkinson’s disease
Through this partnership, Merck gains access to Valo’s advanced AI-powered human causal biology and discovery platforms, which the drugmaker will use to identify new disease targets and develop preclinical compounds.